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Abstract
Objective—To examine the proposed disruptive mood dysregulation disorder (DMDD)
diagnosis in a child psychiatric outpatient population. Evaluation of DMDD included 4 domains:
clinical phenomenology, delimitation from other diagnoses, longitudinal stability, and association
with parental psychiatric disorders.
Method—Data were obtained from 706 children aged 6–12 years who participated in the
Longitudinal Assessment of Manic Symptoms (LAMS) study (sample was accrued from
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November 2005 to November 2008). DSM-IV criteria were used, and assessments, which
included diagnostic, symptomatic, and functional measures, were performed at intake and at 12
and 24 months of follow-up. For the current post hoc analyses, a retrospective diagnosis of
DMDD was constructed using items from the K-SADS-PL-W, a version of the Schedule for
Affective Disorders and Schizophrenia for School-Age Children, which resulted in criteria closely
matching the proposed DSM-5 criteria for DMDD.
Results—At intake, 26% of participants met the operational DMDD criteria. DMDD+ vs
DMDD– participants had higher rates of oppositional defiant disorder (relative risk [RR] = 3.9, P
< .0001) and conduct disorder (RR = 4.5, P < .0001). On multivariate analysis, DMDD+
participants had higher rates of and more severe symptoms of oppositional defiant disorder (rate
and symptom severity P values < .0001) and conduct disorder (rate, P < .0001; symptom severity,
P = .01), but did not differ in the rates of mood, anxiety, or attention-deficit/hyperactivity
disorders or in severity of inattentive, hyperactive, manic, depressive, or anxiety symptoms. Most
of the participants with oppositional defiant disorder (58%) or conduct disorder (61%) met DMDD
criteria, but those who were DMDD+ vs DMDD– did not differ in diagnostic comorbidity,
symptom severity, or functional impairment. Over 2-year follow-up, 40% of the LAMS sample
met DMDD criteria at least once, but 52% of these participants met criteria at only 1 assessment.
DMDD was not associated with new onset of mood or anxiety disorders or with parental
psychiatric history.
Conclusions—In this clinical sample, DMDD could not be delimited from oppositional defiant
disorder and conduct disorder, had limited diagnostic stability, and was not associated with
current, future-onset, or parental history of mood or anxiety disorders. These findings raise
concerns about the diagnostic utility of DMDD in clinical populations.
Irritable mood and temper outbursts are common in youth referred for psychiatric
treatment.1,2 They are also the core features of the proposed diagnosis disruptive mood
dysregulation disorder (DMDD) in DSM-5.3 DMDD is characterized primarily by frequent,
severe, recurrent temper outbursts and chronically irritable and/or angry mood, both of
which must be present for at least a year. The DSM-5 Work Groups raised concerns that
many youth with severe, nonepisodic irritable mood are inappropriately diagnosed with
bipolar disorder.4 The DMDD diagnosis was constructed to capture the phenomenology of
youth with severe, chronic irritability, with the goal of reducing the chance that youth with
this phenotype would receive a bipolar diagnosis.
The DSM-5 Work Groups note that there is currently relatively limited research to support
the DMDD diagnosis.4 Most available studies focus on an overlapping but not identical
construct called severe mood dysregulation (SMD). SMD includes the core criteria of
DMDD, but also requires symptoms of chronic hyperarousal such as insomnia, agitation,
distractibility, racing thoughts, flight of ideas, pressured speech, and intrusiveness.5
Published research on SMD has primarily been from a carefully phenotyped cohort of 146
youth referred to the National Institute of Mental Health (NIMH) Intramural Program.6 The
youth with SMD were predominantly male (66%) and had high lifetime rates of attention-
deficit/hyperactivity disorder (ADHD; 85%), oppositional defiant disorder (86%), and
anxiety disorders (58%). About 16% met lifetime criteria for major depressive disorder
(MDD). The youth with SMD were shown to be different from youth with a specified
phenotype of bipolar I disorder (requiring distinct episodes of manic symptoms, including
either elated mood or grandiosity) on a number of domains, including lower familial rates of
bipolar disorder, lower onset rates of manic and hypomanic episodes over prospective
follow-up, and differences on several neuropsychological domains and measures of brain
structure and functioning.6
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Other studies relevant to the SMD/DMDD phenotype have been post hoc analyses of large
datasets in which a retrospective diagnosis of SMD was derived from the existing
phenotypic variables. In the Great Smoky Mountains Study, 1.8% of the sample met SMD
criteria with severe functional impairment, which made it much more common than bipolar
disorder (0.1% of the sample).7 The severely impaired SMD youth from this community
sample were predominantly male (66%), but differed from those in the NIMH studies, as
only about 32% met criteria for ADHD; 42%, for oppositional defiant disorder; and 21%,
for any anxiety disorder. In addition, there was very little longitudinal stability of the SMD
diagnosis (83% met SMD criteria at only 1 wave). A retrospective SMD diagnosis was
applied to 4 large aggregated community samples and 2 large clinical samples, which were
assessed using the NIMH Diagnostic Interview Schedule-IV.6 Preliminary analyses
indicated that in the community samples, 15% of youth with oppositional defiant disorder
met SMD criteria, as did about 25% of the youth with oppositional defiant disorder in the
clinical samples.
Additional data specific to the DMDD diagnosis are needed; however, given the time
constraints involved with the release of the upcoming DSM-5, carefully performed
prospective studies are not possible. One way to evaluate DMDD is to take data from
existing cohorts and retrospectively construct a DMDD diagnosis, similar to what was done
for SMD. The Longitudinal Assessment of Manic Symptoms (LAMS) study is one source
that can provide suitable data, as participants were sampled from all children presenting for
new evaluation at 9 different university-affiliated clinics and were carefully assessed using
semistructured interviews.
In order to evaluate the validity of the DMDD diagnosis, it is useful to keep in mind the 5
phases of systematic study proposed by Robins and Guze8 that are necessary to validate a
particular diagnostic classification in psychiatry. Using the LAMS cohort, we can provide
relevant data on 4 of these phases: (1) clinical description, (2) delimitation from other
disorders, (3) follow-up study, and (4) family study. In this article, we examine the clinical
phenomenology of LAMS participants who met a DMDD diagnostic phenotype at intake
and evaluate whether the DMDD phenotype can be delimited from other diagnoses, is stable
over a 2-year follow-up period, and predicts new onset of DSM-IV diagnoses. Lastly, we
assess the association of the DMDD phenotype with parental history of different psychiatric
disorders.
METHOD
Detailed description of the LAMS study methodology has been published previously.9,10
The LAMS study screened children presenting for initial psychiatric assessment at 9
outpatient clinics affiliated with 4 academic medical centers: Case Western Reserve
University, Cincinnati Children's Medical Center, the Ohio State University, and the
University of Pittsburgh Medical Center. The institutional review boards at each site
approved all study procedures prior to commencing the study. Parents provided written
consent to complete the screening procedure described below. Parents then provided written
consent, and children assented to participate in the intake assessment and longitudinal study.
The sample was accrued from November 14, 2005, to November 28, 2008.
Participant Ascertainment
Parents/guardians of eligible children who were new patients to LAMS outpatient clinics
completed the Parent General Behavior Inventory 10-Item Mania Scale (PGBI-10M) to
screen for elevated symptoms of mania (ESM).11 Total scores range from 0 to 30. Each
patient whose parent or guardian rated the child at or above a score of 12 (ESM+) was
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invited to participate in the study. Subsequently, a smaller demographically matched
comparison group of patients who scored 11 or lower (ESM–) was also enrolled.
To be eligible, patients must (1) not have received mental health treatment in the LAMS-
affiliated outpatient clinics within the past year, (2) be 6–12 years of age, (3) speak English,
(4) have an accompanying parent/guardian who speaks English, and (5) not have a sibling or
other child in the same household who already participated in the LAMS screening.9
The PGBI-10M screen was completed by the parents/guardians of 2,622 children; 1,124
(43%) of the children screened ESM+. Of these, 621 (55%) decided to continue in the next
study phases. There were no sociodemographic differences between children/families
agreeing to enroll in the longitudinal study and those who did not. ESM–children were
sampled with replacement, resulting in inclusion of 86 children without ESM.9
Intake Assessment
Diagnoses—Children and their parents/guardians completed the Schedule for Affective
Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-
SADS-PL)12 with additional depression and manic symptom items derived from the
Washington University in St. Louis Kiddie Schedule for Affective Disorders and
Schizophrenia (WASH-U K-SADS),13 as well as items to screen for pervasive
developmental disorders. The resulting instrument, the K-SADS-PL-W, is a semistructured
interview that assesses current and lifetime psychiatric diagnoses.
Unmodified DSM-IV diagnostic criteria were used, except the criteria for bipolar disorder
not otherwise specified (NOS) from the Course and Outcome of Bipolar Youth study14 were
applied: (1) elated mood plus 2 associated symptoms of mania (eg, grandiosity, decreased
need for sleep) or irritable mood plus 3 associated symptoms, (2) change in functioning
(increase or decrease), (3) the abnormal mood and associated symptoms must be present for
a total of at least 4 hours within a 24-hour period, and (4) the participant must have had at
least 4 days of meeting the above-noted criteria in his or her lifetime. Bipolar spectrum
diagnoses included all participants who met criteria for cyclothymia, bipolar disorder NOS,
or bipolar I or II disorder. All diagnoses were reviewed and confirmed by a licensed child
psychiatrist or psychologist.
Symptomatic assessment—Mood symptoms were assessed in 2 ways: occurring
specifically within the context of a mood episode (ie, “filtered” ratings) and irrespective of
association with a distinct change in mood (“unfiltered” ratings). Filtered ratings were
quantified using the K-SADS Depression Rating Scale–10 item15 and the K-SADS Mania
Rating Scale16 constructed from the K-SADS-PL-W mood items. Unfiltered ratings were
obtained regarding the past 2 weeks using the Young Mania Rating Scale17 and the
Children's Depression Rating Scale-Revised (CDRS-R).18,19 As irritability is the primary
symptom of the DMDD phenotype, we removed this item from the total scores so that we
could look at nonoverlapping mood symptomatology.
Questionnaires assessed dimensions of nonmood symptoms. Parent-reported scores on the
ADHD, oppositional defiant disorder, and conduct disorder subscales of the Child and
Adolescent Symptom Inventory-4R (CAASI-4R)20 were examined. The parent-completed
Screen for Child Anxiety Related Emotional Disorders (SCARED-P)21 quantified symptoms
of anxiety over the past 6 months.
Functional assessment—Study interviewers completed the Children's Global
Assessment Scale22 to quantify current impairment and most severe level of impairment
over the participants’ lifetime.
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Demographics and school and treatment history—These were obtained by direct
interview of the primary caregiver.
Family history—The Family History Screen23 collected information on psychiatric
disorders in the participants’ biological parents.
Longitudinal Follow-Up Assessments
The instruments from the intake assessment were repeated every 12 months. However, the
time frame for lifetime measures (ie, past psychiatric diagnoses) was for the prior 12
months.
Retrospective DMDD Diagnosis
The operational definition of DMDD used the current ratings of the following items from
the K-SADS-PL-W, resulting in criteria closely matching the proposed DSM-5 criteria.3
• Severe recurrent temper outbursts. This criterion consisted of the “loses temper”
item: “severe temper outbursts 2–5 times per week” at threshold.
• Chronic irritability. This criterion consisted of both the “easily annoyed or
angered” (“easily annoyed or angered daily or almost daily”) and “angry or
resentful” (“angry or resentful daily or almost daily”) items at threshold.
• Duration. Participants who completed the K-SADS-PL-W oppositional defiant
disorder supplement were assessed for whether the symptoms were present for at
least 6 months, independent of whether they met full criteria for oppositional
defiant disorder. This duration differs from DMDD criterion D, which states that
symptoms must be present for an interval of 12 or more months and that there
cannot be 3 or more consecutive months during the interval when the person was
without the symptoms of criteria A–C.
• Impairment in more than 1 setting. The oppositional defiant disorder supplement
determined whether impairment occurred in at least 2 settings.
• Episodes of elated mood plus manic-specific symptoms lasting more than 1 day
cannot be present. DMDD criterion H excludes participants with episodic manic
symptoms lasting more than 1 day at a time, thus excluding youth with bipolar I or
II disorders and potentially some with bipolar disorder NOS and cyclothymia.
However, because whether the DMDD phenotype can be delimited from bipolar
disorder (other than by using an exclusion criterion) is a question to be evaluated,
participants with bipolar spectrum diagnoses were included in the DMDD group.
• Symptoms are not occurring exclusively during a psychotic or mood disorder or are
better accounted for by another disorder. LAMS interviewers rate symptoms in the
oppositional defiant disorder section only if they do not occur exclusively during a
psychotic or mood disorder or are clearly accounted for by another disorder.
The proposed DSM-5 criteria for DMDD specify that individuals meeting criteria for
DMDD and oppositional defiant disorder should be given a diagnosis of DMDD. As a goal
of these analyses is to evaluate whether DMDD can be delimited from existing DSM-IV
diagnoses, this criterion was not applied.
One participant did not have complete information on duration and impairment and was
excluded from analyses.
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Statistical analyses were performed using IBM SPSS version 20.0 (Armonk, New York).
Univariate analyses used standard parametric (t, χ2) or nonparametric (Mann-Whitney U)
tests. Multivariate logistic regression models were built with group (eg, DMDD+) as the
outcome variable. Variables that had a potential association with the outcome variable at a
level of P < .10 on the univariate tests were entered using a forward conditional method with
P < .05 as criteria for entry and P > .10 for removal.24
For some analyses, participants with oppositional defiant disorder and participants with




Severe, recurrent temper outbursts were present in 52% of the LAMS sample, and chronic
irritability was present in 35%. The DMDD phenotype was present in 26% (n = 184) of
LAMS participants and was significantly more common in the ESM+ vs ESM– participants
(28% vs 14%; relative risk [RR] = 1.99; 95% confidence interval [CI], 1.16–3.41; P = .006),
so ESM status was included as a potential covariate in the multivariate models. An
additional 5% (n = 34) of the sample had both severe, recurrent temper outbursts and
chronic irritability, but did not meet full criteria for DMDD because they did not have
impairment in 2 settings (n = 27), did not meet duration criteria (n = 3), or met neither the
impairment nor duration criteria (n = 4).
Table 1 compares the 184 DMDD+ participants with the 522 DMDD– participants on
factors measured at intake. DMDD+ participants did not significantly differ from DMDD–
participants in the rates of bipolar spectrum diagnoses, any depressive disorders, MDD, or
anxiety disorders. DMDD+ participants had higher rates of disruptive behavior disorders,
dysthymia, elimination disorders, and ADHD as compared to the DMDD– group. In the
multivariate model, only oppositional defiant disorder and conduct disorder remained
significantly associated with DMDD (oppositional defiant disorder: Wald χ2 = 124, odds
ratio [OR] = 68.7 [95% CI, 32.6–144.7], P < .0001; conduct disorder: Wald χ2 = 92, OR =
77.8 [95% CI, 32.0–189.1], P < .0001).
On dimensional measures of psychopathology, DMDD+ youth had significantly higher total
scores on the Young Mania Rating Scale, CDRS-R, and K-SADS Mania Rating Scale (all
with the irritability item removed), the K-SADS Depression Rating Scale, and the
CAASI-4R ADHD subscales and oppositional defiant disorder and conduct disorder scales.
On multivariate analysis, only the CAASI-4R oppositional defiant disorder and conduct
disorder total scores were significantly associated with DMDD (CAASI-4R oppositional
defiant disorder: Wald χ2 = 45, OR = 1.16 [95% CI, 1.11–1.21], P < .0001; CAASI-4R
conduct disorder: Wald χ2 = 6.1, OR = 1.05 [95% CI, 1.01–1.10], P = .01), along with
nonwhite race becoming significantly associated with DMDD in the model (Wald χ2 = 5.2,
OR = 1.58 [95% CI, 1.07–2.35], P = .02).
Youth with DMDD were more impaired than those without DMDD. However, they were not
more likely to have repeated a grade, received special educational intervention, taken
psychotropic medication, or have a history of inpatient psychiatric hospitalization.
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Participants who did not complete any follow-up assessments were less likely to live with
both biological parents than those who did complete a follow-up assessment (20% vs 35%);
otherwise, there were no significant demographic differences between groups. There were
no differences among participants without follow-up versus those with follow-up in the rates
of baseline depressive disorders, bipolar spectrum diagnoses, ADHD, anxiety disorders,
psychotic disorders, or oppositional defiant disorder/conduct disorder or in baseline DMDD
and ESM status.
The 12-month assessment was available for 525 participants (74% of the sample), with 21%
meeting DMDD criteria. Of those meeting criteria for DMDD at intake, 53% continued to
meet criteria at 12 months. Of the 111 participants who were DMDD+ at the 12-month
assessment, 71 (64%) were DMDD+ at intake. For comparison, 85% of participants who
met full criteria for ADHD at intake also did so at the 12-month follow-up.
Both 12-month and 24-month follow-up assessments were available in 433 participants
(61% of the sample). Of those 433 participants, 172 (40%) met DMDD criteria for at least 1
assessment, including 27% of the ESM– subjects. Of those 172 participants who were
DMDD+ at intake or follow-up, 90 (52%) met criteria at only 1 assessment, while 50 (29%)
met criteria at 2 assessments and 32 (19%) met criteria for all 3 assessments. In comparison,
of the participants who met criteria for ADHD at intake or follow-up, 18% met criteria at
only 1 assessment; 21%, at 2 assessments; and 61%, at all 3 assessments.
In participants with both follow-up visits, DMDD at intake was not associated with new
onset of bipolar spectrum diagnoses (including bipolar I and II disorders), depressive
disorders (including MDD), anxiety disorders, psychotic disorders, or conduct disorder over
follow-up (Table 2). A diagnosis of DMDD at either intake or follow-up was significantly
associated with a diagnosis at intake or follow-up of oppositional defiant disorder/conduct
disorder (71% of those with oppositional defiant disorder/conduct disorder had DMDD vs
3% without oppositional defiant disorder/conduct disorder; χ2 = 277, P < .0001) and ADHD
(44% vs 23%; χ2 = 20.0, P < .0001), but not MDD (42% vs 38%, χ2 = 0.4, P = .52), any
depressive disorder (44% vs 37%, χ2 = 2.0, P = .16), bipolar I and II disorders (41% vs
38%; χ2 = 0.4, P = .52), bipolar spectrum diagnoses (44% vs 36%; χ2 = 3.1, P = .08), any
anxiety disorder (41% vs 38%; χ2 = 0.4, P = .52), or psychotic disorder (52% vs 38%; χ2 =
1.9, P = .17).
Distinction From Oppositional Defiant Disorder and Conduct Disorder
At the intake assessment, 58% of youth with oppositional defiant disorder and 61% of youth
with conduct disorder were DMDD+. Nearly all (96%) of DMDD+ youth met criteria for
oppositional defiant disorder or conduct disorder (RR vs DMDD– = 4.03 [95% CI, 3.44–
4.70]), and 77% met criteria for both ADHD and oppositional defiant disorder/conduct
disorder (RR vs DMDD– = 4.30 [95% CI, 3.52–5.26]; Figure 1). In contrast, 41% of
participants with MDD (RR vs no MDD = 0.96 [95% CI, 0.68–1.36]) and 40% of those with
bipolar spectrum diagnoses (RR vs no bipolar spectrum diagnoses = 0.91 [95% CI, 0.74–
1.13]) had comorbid oppositional defiant disorder or conduct disorder; 27% of MDD (RR vs
no MDD = 0.79 [95% CI, 0.49–1.27]) and 34% of participants with bipolar spectrum
diagnoses (RR vs no bipolar spectrum diagnoses = 1.03 [95% CI, 0.74–1.13]) had both
ADHD and oppositional defiant disorder/conduct disorder. There was no difference in the
rate of DMDD in participants with oppositional defiant disorder/conduct disorder who were
ESM+ (59%) versus those that were ESM– (55%; RR = 1.07 [95% CI, 0.71–1.61]).
Participants with oppositional defiant disorder/conduct disorder who were DMDD+ did not
have significantly different rates of bipolar spectrum diagnoses, depressive disorders,
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anxiety disorders, or ADHD compared to those who were DMDD– (Table 3). DMDD+ vs
DMDD– oppositional defiant disorder/conduct disorder participants did not differ in Young
Mania Rating Scale, CDRS-R, K-SADS Depression Rating Scale and K-SADS Mania
Rating Scale total scores, CAASI-4R ADHD subscales, SCARED-P total scores, and
Children's Global Assessment Scale.
In the participants diagnosed with oppositional defiant disorder or conduct disorder (n =
180) at intake who also had both follow-up assessments, those with DMDD did not differ
significantly from those without DMDD in the rates of new onset of bipolar spectrum
diagnoses (9% vs 18%; RR = 0.5 [95% CI, 0.21–1.22]), depressive disorders (12% vs 12%;
RR = 0.96 [95% CI, 0.39–2.39]), psychotic disorders (3% vs 4%; RR = 0.75 [95% CI, 0.16–
3.61]), or anxiety disorders (13% vs 16%; RR = 0.86 [95% CI, 0.39–1.89]).
Parental Psychiatric History
DMDD+ participants at intake did not significantly differ from DMDD– participants in the
rates of a screening diagnosis in at least 1 biological parent of depression (DMDD+ 67% vs
DMDD– 63%, RR = 1.06 [95% CI, 0.94–1.20]), bipolar disorder (23% vs 20%, RR = 1.19
[95% CI, 0.86–1.66]), anxiety disorder (49% vs 55%, RR = 0.88 [95% CI, 0.74–1.05]),
psychotic disorder (14% vs 11%, RR = 1.31 [95% CI, 0.84–2.05]), substance use disorder
(48% vs 45%, RR = 1.06 [95% CI, 0.88–1.26]), ADHD (30% vs 26%, RR = 1.12 [95% CI,
0.86–1.47]), or conduct disorder (43% vs 39%, RR = 1.10 [95% CI, 0.90–1.34]).
DISCUSSION
The results of these analyses indicate that severe recurrent temper outbursts and chronic
irritability are common symptoms in youth presenting for outpatient psychiatric assessment.
Moreover, the proposed DMDD diagnosis is common in university child psychiatric
outpatient settings. However, DMDD did not identify a phenotype that was clearly
differentiated from disruptive behavioral disorders or had a distinct course and outcome,
substantial longitudinal stability, or an association with a parental history of mood or anxiety
disorders. In comparison to other diagnoses in the LAMS cohort, the degree of overlap
between disruptive behavior disorders (oppositional defiant disorder/conduct disorder) and
DMDD was far greater than the overlap between oppositional defiant disorder/conduct
disorder and mood disorders, and the longitudinal stability of the DMDD diagnosis was far
less than the stability of ADHD.
The study results should be considered with regard to the following limitations. The LAMS
participants were disproportionately recruited to have elevated PGBI-10M scores, and
DMDD was associated with increased PGBI-10M scores. The PGBI-10M has 2 items that
assess irritability, although it is in the context of unusually happy mood: (1) periods of
feeling unusually happy as well as struggling to control inner feelings of rage and (2)
periods of feeling unusually happy when almost everything got on their nerves. Therefore,
the sample may not be representative of the cohort of all participants who were screened,
which could affect the rates of DMDD and the phenomenology of the DMDD+ participants
assessed. However, it is notable that ESM status at baseline was not a significant factor in
the multivariate analyses. DMDD criteria were extracted from K-SADS questions so that
only a retrospective diagnosis could be applied. The instrument used for ascertaining family
history (the Family History Screen) uses a few screening questions to determine diagnoses
in family members; these results should be interpreted with caution. The majority of
participants presented to outpatient services at academic psychiatry departments, so results
may not generalize to other clinical settings or to community samples.
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In LAMS, DMDD could not be clearly differentiated from oppositional defiant disorder and
conduct disorder. On multivariate assessment, DMDD status at intake was associated only
with oppositional defiant disorder and conduct disorder diagnoses, and these associations
were not affected by ESM status. At intake, the majority of youth with oppositional defiant
disorder (59%) or conduct disorder (61%) also met criteria for DMDD. These percentages
are substantially higher than those found in some clinical cohorts, where approximately 25%
of the oppositional defiant disorder participants met DMDD criteria.6 However, a clinical
sample from a recent treatment study25 had similar levels of overlap of SMD with
oppositional defiant disorder and conduct disorder, as 44% of participants with oppositional
defiant disorder and 67% of those with conduct disorder met SMD criteria. The oppositional
defiant disorder/conduct disorder youth with DMDD did not differ from those without
DMDD in age, sex, rates of comorbid disorders or of onset of new disorders over follow-up,
dimensional psychopathology, or functional impairment. The degree of diagnostic overlap
between DMDD and oppositional defiant disorder/conduct disorder (RR = 4.0) was many
orders of magnitude greater than for other mood disorders in the sample such as MDD or
bipolar spectrum diagnoses, both of which were not significantly associated with
oppositional defiant disorder/conduct disorder (RR, 0.9–1.0).
DMDD was not specifically associated with disorders other than oppositional defiant
disorder and conduct disorder, although DMDD was present in 40%–50% of youth
diagnosed with anxiety, depressive, and bipolar spectrum disorders during the first 2 years
of the study. On multivariate analysis, DMDD was associated with dimensional
psychopathology only in the domains of disruptive behavior disorders. DMDD at intake did
not specifically predict future onset of mood or anxiety disorders over follow-up. Finally,
DMDD was not associated with a parental history of ADHD or mood, anxiety, conduct, or
substance use disorders. These findings stand in contrast to results from epidemiologic
studies,7,26–28 which found that chronic irritability (including SMD) in childhood was
associated with future onset of depressive and anxiety disorders.
Multiple factors may contribute to the disparate findings. Participant ascertainment may play
a key role, as there are potential differences in the phenomenology of depressed and DMDD
youth who are seeking treatment and enriched for the presence of manic symptomatology
versus those in the community. In addition, epidemiologic samples would be expected to
have much lower rates of DMDD and mood disorders in general, and bipolar disorder in
particular, than the LAMS sample. Low numbers of participants with bipolar disorder can
lead to difficulty in obtaining accurate estimates of the association of DMDD with
bipolarity. Operationalization of the retrospective diagnoses could affect results, as some
studies7,28 included irritability items drawn from the depression section of the assessment,
which could increase the association of DMDD and later depression. Age of the participants
and the duration of follow-up could also influence the findings. The LAMS cohort was 9½
years old on average at intake and was followed for only 2 years to date, so they were well
before the maximum age of risk for onset of depression or bipolar disorder at the end of
follow-up. In contrast, the epidemiologic studies often followed participants into young
adulthood.7,26 These differences in methodology reinforce the need for multiple studies
(preferably with repeated assessment and extended longitudinal follow-up) using different
sampling and assessment strategies, to determine whether a clearer consensus on DMDD
can emerge.
DMDD was not associated with bipolar disorder overall, or with a family history of manic
symptoms. This lack of association lends support to the conceptualization that chronic
irritability and temper outbursts are not specific manifestations of pediatric bipolar disorder.
However, given that 44% of youth with bipolar I or II disorder would have met criteria for
DMDD except for the bipolar diagnostic exclusion, clinicians will need to carefully assess
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for the presence of manic symptomatology in youth who have the DMDD phenotype, or
children who actually have bipolar disorder could be mislabeled as having DMDD.
In the LAMS cohort, DMDD was a common but somewhat transient phenotype that could
not be clearly differentiated from disruptive behavior disorders (oppositional defiant
disorder and conduct disorder) and was otherwise not specifically associated with other
diagnoses or symptom domains. These findings indicate that additional research will be
required to clarify whether the DMDD phenotype is a valid, separate diagnostic entity.
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■ The proposed disruptive mood dysregulation disorder (DMDD) diagnosis is not
clearly differentiated from oppositional defiant disorder and conduct disorder in
children presenting for psychiatric treatment.
■ Youth presenting for treatment with disruptive behavioral, anxiety, and mood
disorders will frequently meet the proposed diagnostic criteria for DMDD.
■ Many youth with bipolar disorder will meet the primary symptom criteria for
DMDD; therefore, careful assessment for manic symptomatology is required for
children who present with features of DMDD.
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Overlap of Disruptive Mood Dysregulation Disorder (DMDD), Attention-Deficit/
Hyperactivity Disorder (ADHD), and Oppositional Defiant Disorder (ODD)/Conduct
Disorder (CD)
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Table 1
Factors at Intake by Disruptive Mood Dysregulation Disorder Status




Sex, male, % 66 68 0.96 (0.86–1.09) NS
Race, white, % 59 66 0.89 (0.77–1.01) .06
Age, mean ± SD, y 9.3 ± 1.8 9.5 ± 2.0 t = 1.2 NS
Lives with both biological parents, % 28 34 0.84 (0.65–1.09) NS
Primary caretaker education, %
    No or some high school 13 10 Z = 1.8 .08
    GED or high school diploma 25 26
    Some post–high school, no degree 30 26
    Associate's degree or other post–high school certification 21 17
    Bachelor's degree or higher 12 21
Diagnoses, %
Any mood disorder 44 39 1.13 (0.93–1.37) NS
Any bipolar spectrum diagnosis 24 23 1.06 (0.78–1.43) NS
    Bipolar I/II disorder 9 11 0.78 (0.46–1.33) NS
    Cyclothymia/bipolar disorder NOS 15 12 1.32 (0.87–2.00) NS
Any depressive disorder 20 17 1.21 (0.85–1.70) NS
    MDD 7 7 0.92 (0.48–1.73) NS
    Dysthymic disorder 4 2 2.84 (1.09–7.53) .03
    Depressive disorder NOS 9 8 1.15 (0.67–1.97) NS
Oppositional defiant disorder or conduct disorder 96 24 4.03 (3.44–4.70) < .0001
    Oppositional defiant disorder 78 20 3.94 (3.26–4.77) < .0001
    Conduct disorder 18 4 4.46 (2.66–7.53) < .0001
ADHD 79 61 1.29 (1.17–1.43) < .0001
Any anxiety disorder 20 20 0.96 (0.69–1.35) NS
Psychotic disorder 2 2 1.03 (0.34–3.25) NS
Pervasive developmental disorder 3 7 0.44 (0.19–1.02) .04
Elimination disorders 25 18 1.39 (1.02–1.89) .04
Dimensional measures of psychopathology, mean ± SD
YMRS total score
a 15.5 ± 7.7 13.1 ± 8.0 t = 3.5 .0004
CDRS-R total score
a 33.3 ± 9.5 30.6 ± 10.2 t = 3.2 .002
K-SADS Depression Rating Scale total score 7.9 ± 5.7 6.6 ± 6.0 t = 2.6 .009
K-SADS Mania Rating Scale total score
a 10.8 ± 8.4 7.7 ± 8.0 t = 4.4 < .0001
CAASI-4R subscale score
    ADHD—inattentive 19.5 ± 6.1 17.4 ± 6.7 t = 3.7 .0001
    ADHD—hyperactive/impulsive 17.9 ± 6.7 15.5 ± 6.9 t = 4.1 < .0001
    ADHD—combined 37.4 ± 11.3 32.9 ± 12.1 t = 4.4 < .0001
    Oppositional defiant disorder 19.2 ± 4.5 14.1 ± 6.0 t = 12.0 < .0001
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DMDD+ (n=184) DMDD– (n = 522) Test Statistic/Relative
Risk (95% CI)
P Value
    Conduct disorder 8.2 ± 5.5 4.5 ± 4.5 t = 8.2 < .0001
SCARED-P score 18.2 ± 12.7 18.2 ± 14.1 t = 0.0 NS
Functioning
CGAS score (current), mean ± SD 50.7 ± 9.1 56.0 ± 10.3 t = 6.6 < .0001
CGAS score (most severe past), mean ± SD 47.7 ± 10.4 50.1 ± 9.6 t = 2.3 .024
Ever repeated a grade, % 16 17 0.96 (0.66–1.41) NS
Ever received special education class or behavioral
intervention in school, %
28 30 0.93 (0.71–1.21) NS
Lifetime treatment history, %
Psychotropic medication 59 62 0.95 (0.83–1.09) NS
Psychiatric hospitalization 10 9 1.18 (0.71–1.96) NS
Abbreviations: ADHD = attention-deficit/hyperactivity disorder, CAASI-4R = Child and Adolescent Symptom Inventory-4R, CDRS-R =
Children's Depression Rating Scale-Revised, CGAS = Children's Global Assessment Scale, CI = confidence interval, DMDD– = did not meet
criteria for disruptive mood dysregulation disorder, DMDD+ = met criteria for disruptive mood dysregulation disorder, GED = General
Equivalency Diploma, K-SADS = Schedule for Affective Disorders and Schizophrenia for School-Age Children, MDD = major depressive
disorder, NOS = not otherwise specified, NS = nonsignificant, SCARED-P = Screen for Child Anxiety Related Emotional Disorders, YMRS =
Young Mania Rating Scale.
a
Irritability item not included in the total score.
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Table 2
New Onset of Disorder at 12- or 24-Month Follow-Up by Disruptive Mood Dysregulation Disorder Status at
Intake, %
Disorder With New Onset at 12 or 24 Mo DMDD+ at Intake DMDD– at Intake Relative Risk (95% CI) P Value
Bipolar spectrum disorder 8.5 10.1 0.84 (0.41–1.70) NS
Bipolar I/II disorder 5.5 8.0 0.69 (0.31–1.53) NS
Depressive disorder 11.3 9.1 1.26 (0.68–2.31) NS
Major depressive disorder 4.7 4.1 1.13 (0.45–2.81) NS
Anxiety disorder 13.3 9.5 1.40 (0.79–2.48) NS
Conduct disorder 3.4 2.2 1.55 (0.49–4.94) NS
Psychotic disorder 2.9 2.2 1.33 (0.42–4.26) NS
Abbreviations: CI = confidence interval, DMDD- = did not meet criteria for disruptive mood dysregulation disorder, DMDD+ = met criteria for
disruptive mood dysregulation disorder, NS = nonsignificant.
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Table 3
Factors at Intake by Disruptive Mood Dysregulation Disorder Status in Participants With Oppositional Defiant
Disorder or Conduct Disorder




Sex, male, % 67 74 0.90 (0.78–1.05) NS
Race, white, % 58 65 0.90 (0.75–1.08) NS
Age, mean ± SD, y 9.3 ± 1.8 9.5 ± 2.0 t = 1.2 NS
Lives with both biological parents, % 28 27 1.05 (0.72–1.52) NS
Primary caretaker education, %
    No or some high school 13 20 Z = 1.9 .06
    GED or high school diploma 25 29
    Some post–high school, no degree 29 24
    Associate's degree or other post–high school certification 22 15
    Bachelor's degree or higher 12 12
Diagnoses, %
Any mood disorder 42 44 0.94 (0.72–1.22) NS
Any bipolar spectrum diagnosis 22 20 1.10 (0.70–1.72) NS
Any depressive disorder 19 24 0.80 (0.52–1.23) NS
ADHD 80 75 1.07 (0.94–1.21) NS
Any anxiety disorder 20 22 0.91 (0.58–1.43) NS
Psychotic disorder 2 3 0.53 (0.12–2.32) NS
Pervasive developmental disorder 3 1 4.23 (0.52–34.7) NS
Dimensional measures of psychopathology, mean ± SD
YMRS total score
a 15.5 ± 7.8 15.0 ± 7.6 t = 0.6 NS
CDRS-R total score
a 33.1 ± 9.5 32.3 ± 10.3 t = 0.7 NS
K-SADS Depression Rating Scale total score 7.8 ± 5.7 7.1 ± 5.9 t = 1.0 NS
K-SADS Mania Rating Scale total score
a 10.6 ± 8.3 8.8 ± 7.8 t = 1.9 .06
CAASI-4R subscale score
    ADHD—inattentive 19.6 ± 6.0 18.4 ± 6.3 t = 1.7 NS
    ADHD—hyperactive/impulsive 18.1 ± 6.6 17.3 ± 6.5 t = 1.0 NS
    ADHD—combined 37.7 ± 11.1 35.7 ± 11.5 t = 1.5 NS
SCARED-P score 17.8 ± 12.4 17.3 ± 12.4 t = 0.3 NS
Functioning, mean ± SD
CGAS score (current) 50.8 ± 9.2 51.5 ± 10.3 t = 0.6 NS
CGAS score (most severe past) 48.1 ± 10.3 46.1 ± 10.3 t = 1.3 NS
Abbreviations: ADHD = attention-deficit/hyperactivity disorder, CAASI-4R = Child and Adolescent Symptom Inventory-4R, CDRS-R =
Children's Depression Rating Scale-Revised, CGAS = Children's Global Assessment Scale, CI = confidence interval, DMDD– = did not meet
criteria for disruptive mood dysregulation disorder, DMDD+ = met criteria for disruptive mood dysregulation disorder, GED = General
Equivalency Diploma, NS = nonsignificant, SCARED-P = Screen for Child Anxiety Related Emotional Disorders, YMRS = Young Mania Rating
Scale.
a
Irritability item not included in the total score.
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